Accueil » Communiqués de presse » Valbiotis announces completion of recruitment for the Phase II/III REVERSE-IT clinical study with TOTUM•63 against prediabetes, in partnership with Nestlé Health Science.
Les communiqués de presse
28Jul2022
Valbiotis announces completion of recruitment for the Phase II/III REVERSE-IT clinical study with TOTUM•63 against prediabetes, in partnership with Nestlé Health Science.
